Sponsored by
UCSF is developing a new, advanced type of CAR-T therapy using a novel technology called synthetic notch (synNotch). A Phase 1 study to test safety just opened this week for patients with newly diagnosed EGFRvIII+ GBM with unmethylated MGMT promotor status, and a second trial is in the works for 2025.